Quick Answer
Amylyx Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$87.37M -77.1% |
$380.79M +1612.9% |
$22.23M +7700.0% |
$285.0K | — |
| Revenue (ASC 606) | $0.00 -100.0% |
$87.37M -77.1% |
$380.79M +1612.9% |
$22.23M | — | — |
| Net Income | -$144.74M +52.0% |
-$301.74M -712.4% |
$49.27M +124.8% |
-$198.38M -125.6% |
-$87.93M | — |
| Diluted EPS | -$1.53 +65.5% |
-$4.43 -732.9% |
$0.70 +120.6% |
-$3.39 +74.6% |
-$13.35 | — |
| Total Assets | $332.64M +71.8% |
$193.63M -62.6% |
$517.45M +32.2% |
$391.45M +270.6% |
$105.61M | — |
| Cash and Equivalents | $226.65M +192.9% |
$77.39M -54.5% |
$170.20M +172.2% |
$62.53M +24.6% |
$50.19M | — |
| Stockholders Equity | $305.26M +85.3% |
$164.76M -62.0% |
$433.43M +27.3% |
$340.61M +325.3% |
-$151.17M -126.6% |
-$66.72M |
| R&D Expense | $90.40M -13.1% |
$104.08M -18.8% |
$128.19M +37.2% |
$93.45M +112.2% |
$44.04M | — |
| Operating Income | -$153.29M +51.3% |
-$314.73M -911.1% |
$38.80M +119.3% |
-$201.34M -143.5% |
-$82.69M | — |
| Shares Outstanding | 109.88M +60.1% |
68.63M +1.4% |
67.71M +1.8% |
66.51M +847.4% |
7.02M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$34.39M | +52.7% | +17.0% |
| Diluted EPS | September 30, 2025 | -$0.37 | +65.4% | +19.6% |
| Total Assets | September 30, 2025 | $362.74M | +44.7% | +86.4% |
| Cash and Equivalents | September 30, 2025 | $225.18M | +213.4% | +287.7% |
| Stockholders Equity | September 30, 2025 | $332.00M | +69.2% | +97.8% |
| R&D Expense | September 30, 2025 | $19.86M | -6.5% | -27.0% |
| Operating Income | September 30, 2025 | -$36.03M | +52.4% | +15.9% |
| Shares Outstanding | September 30, 2025 | 109.77M | +60.1% | +23.1% |
- Amylyx Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported Net Income of -$144.74 million for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +52.0% in Net Income compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported Diluted EPS of $1.53 per share (loss) for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +65.5% in Diluted EPS compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported Total Assets of $332.64 million for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +71.8% in Total Assets compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported Cash and Equivalents of $226.65 million for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +192.9% in Cash and Equivalents compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported Stockholders Equity of $305.26 million for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +85.3% in Stockholders Equity compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported R&D Expense of $90.40 million for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed a decrease of -13.1% in R&D Expense compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported Operating Income of -$153.29 million for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +51.3% in Operating Income compared to the prior fiscal year.
- Amylyx Pharmaceuticals, Inc. reported Shares Outstanding of 109.88 million shares for fiscal year 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +60.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: